

November 4, 2024



Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024.

Date: November 11, 2024

Time: 2:30 PM

Format: Fireside Chat & 1x1 Meetings

The Benitec presentation will also be available via live webcast [here](#).

Please contact your Guggenheim representative to schedule a 1x1 meeting with Benitec management.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. ("Benitec" or the "Company") is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary "Silence and Replace" DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec's website at www.benitec.com.

Investor Relations Contact:

Irina Koffler

LifeSci Advisors

Tel: (917) 734-7387

ikoffler@lifesciadvisors.com



Source: Benitec Biopharma Inc.